Humanwell obtains approval for carbocisteine oral solution

Humanwell Healthcare Group (SSE:600079) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Carbocisteine Oral Solution. The newly approved drug is indicated for treating conditions like chronic bronchitis characterized by viscous mucus and difficulty in expectoration. Yichang Humanwell submitted the application in July 2023, with a total research and development investment of approximately CNY7 million. According to market data, the national sales of Carbocisteine Oral Solution totaled CNY670 million in 2024. Humanwell stated that it will proceed with the production and launch of the product based on market demand.